| Eunjin Emily Jang, MD | |
|
1035 116th Ave Ne, Bellevue, WA 98004-4604 | |
| (425) 688-5676 | |
| (425) 739-4667 |
| Full Name | Eunjin Emily Jang |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 7 Years |
| Location | 1035 116th Ave Ne, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134657372 | NPI | - | NPPES |
| 91-1932954 | Other | IL | TAX ID# |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 125070802 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mccd Fl Psychiatry Services Pa | 4880064070 | 206 |
| Mccd Fl Psychiatry Services Pa | 4880064070 | 206 |
| Mccd Fl Psychiatry Services Pa | 4880064070 | 206 |
News Archive
Cypress Systems Inc. has agreed to stop selling yeast beta glucan and has acknowledged the validity of Biothera's patents as part of the settlement of a lawsuit filed in federal district court last March.
Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Currently, only 44 percent of adults in the United States receive an annual flu vaccination. Though the rate has increased in recent years, the change has been slow and marginal.
› Verified 5 days ago
| Entity Name | King County Public Hospital District No 2 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801986070 PECOS PAC ID: 7618880097 Enrollment ID: O20031111000557 |
News Archive
Cypress Systems Inc. has agreed to stop selling yeast beta glucan and has acknowledged the validity of Biothera's patents as part of the settlement of a lawsuit filed in federal district court last March.
Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Currently, only 44 percent of adults in the United States receive an annual flu vaccination. Though the rate has increased in recent years, the change has been slow and marginal.
› Verified 5 days ago
| Entity Name | Overlake Medical Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
Cypress Systems Inc. has agreed to stop selling yeast beta glucan and has acknowledged the validity of Biothera's patents as part of the settlement of a lawsuit filed in federal district court last March.
Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Currently, only 44 percent of adults in the United States receive an annual flu vaccination. Though the rate has increased in recent years, the change has been slow and marginal.
› Verified 5 days ago
| Entity Name | Mccd Fl Psychiatry Services Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659003457 PECOS PAC ID: 4880064070 Enrollment ID: O20230519000385 |
News Archive
Cypress Systems Inc. has agreed to stop selling yeast beta glucan and has acknowledged the validity of Biothera's patents as part of the settlement of a lawsuit filed in federal district court last March.
Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Currently, only 44 percent of adults in the United States receive an annual flu vaccination. Though the rate has increased in recent years, the change has been slow and marginal.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eunjin Emily Jang, MD 1035 116th Ave Ne, Bellevue, WA 98004-4604 Ph: (425) 688-5676 | Eunjin Emily Jang, MD 1035 116th Ave Ne, Bellevue, WA 98004-4604 Ph: (425) 688-5676 |
News Archive
Cypress Systems Inc. has agreed to stop selling yeast beta glucan and has acknowledged the validity of Biothera's patents as part of the settlement of a lawsuit filed in federal district court last March.
Repros Therapeutics Inc. today announced results from an exploratory, efficacy and safety study of its oral investigational product, enclomiphene citrate (Androxal®), in men with secondary hypogonadism who were receiving testosterone replacement treatment. Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.
A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online in the British Medical Journal, could have important implications for determining which men should be screened after the age of 60 and which may not benefit substantially from continued prostate cancer screening.
Currently, only 44 percent of adults in the United States receive an annual flu vaccination. Though the rate has increased in recent years, the change has been slow and marginal.
› Verified 5 days ago
Ted W Farrand, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13451 Se 36th St, Bellevue, WA 98006 Phone: 425-562-1337 Fax: 425-562-1331 | |
Dr. Ashok Shimoji-krishnan, MD, MPH Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13451 Se 36th St, Bellevue, WA 98006 Phone: 425-562-1337 Fax: 425-562-3802 | |
Dr. Romelia Perez, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1611 116th Ave Ne, Suite 132, Bellevue, WA 98004 Phone: 206-795-9797 | |
Dr. Richard Cecil Geary Iii, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1750 112th Ave Ne, B102, Bellevue, WA 98004 Phone: 425-688-5460 Fax: 425-739-4667 | |
Dr. Edward William Freedman, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 1621 114th Ave Se, Suite 221, Bellevue, WA 98004 Phone: 425-455-9900 Fax: 425-688-9987 | |
Ms. Claire Pastor, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1400 112th Ave Se Ste 100, Bellevue, WA 98004 Phone: 425-462-9511 Fax: 425-462-8894 | |
Dr. Megan Christine Riddle, MD PHD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1231 116th Ave Ne Ste 350, Bellevue, WA 98004 Phone: 425-454-1010 Fax: 425-880-5816 |